Table 3.
Comparison to prior clinical trials of sorafenib, demonstrating the presence of greater poor prognostic features in the current study
| Current study (sorafenib arm) N = 74 | SHARP trial (sorafenib arm) N = 299 | Asia-Pacific trial (sorafenib arm) N = 150 | ||
|---|---|---|---|---|
| Median overall esurvival (ITT, months) | 4.8 | 10.7 | 6.5 | |
| ECOG score | 0 | 33.7% | 54% | 25% |
| 1 | 36.5% | 38% | 69% | |
| 2 | 20.3% | 8% | 5% | |
| 3 | 9.5% | 0% | 0% | |
| Hepatitis C | 37.8% | 29% | 10.7% | |
| BCLC ≥ stage C | 100% | 82% | 95% | |
| Gross vascular invasion | 51.3% | 36% | 36% | |
| Extrahepatic metastases | 64.9% | 53% | 69% | |
| Child Pugh B | 58.1% | 5% | 2.7% | |
| AFP, median (ng/mL) | 332 | 44 | N/A | |